1차 진료 POC 진단 시장 : 제품별, 최종 용도별 - 세계 예측(2024-2032년)

The global primary care point-of-care (POC) diagnostics market is expected to grow at a rate of 7% during 2024 and 2032, driven by technological advancements, and the growing demand for rapid & accurate diagnostic solutions.

According to WHO, NCDs claim 41 million lives annually, comprising 74% of global fatalities. The rising geriatric population, coupled with the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases is pushing the demand for POC diagnostic tools. Additionally, the growing demand for decentralized diagnostic testing, in consort with the advancements in technology, such as the development of portable diagnostic devices, are enhancing patient convenience and driving adoption rates.

There is improved awareness about the early diagnosis of ailments. This factor, alongside favorable government initiatives and reimbursement policies are encouraging healthcare providers to integrate POC diagnostics into their practices, fostering market expansion.

The overall primary care POC diagnostics industry is classified based on product, end-use, and region.

The cardiometabolic segment is anticipated to expand at a decent pace till 2032. With the rising prevalence of cardiovascular diseases and diabetes worldwide, there is a growing need for rapid and reliable diagnostic solutions in primary care settings. Companies are investing heavily in the development of POC diagnostic tests for conditions such as cardiac markers, lipid panels, and HbA1c, empowering healthcare providers to make timely interventions and improve patient outcomes.

The diagnostic centers segment is poised to grow robustly through 2032, as they offer a wide range of tests and services to patients in their local communities. With advancements in technology and the increasing availability of portable diagnostic devices, diagnostic centers are now able to offer an expanded menu of POC tests, catering to the diverse needs of patients and healthcare providers alike. As a result, diagnostic centers are poised to experience significant growth in the coming years.

Asia Pacific primary care point-of-care (POC) diagnostics market is set to gain prominence during the study period, propelled by the large population base, coupled with rising healthcare expenditures, and increasing awareness about preventive healthcare. Countries such as China, India, and Japan are witnessing a rapid expansion of their healthcare infrastructure, with a growing number of primary care clinics and diagnostic centers adopting POC testing technologies, thereby fueling industry growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Base estimates and working
• 1.3 Forecast calculations
• 1.4 Data sources
  • 1.4.1 Primary
  • 1.4.2 Secondary
    • 1.4.2.1 Paid sources
    • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Global primary care POC diagnostics market 360 degree synopsis, 2018 - 2032
  • 2.1.1 Regional trends
  • 2.1.2 Product trends
  • 2.1.3 End-use trends

Chapter 3 Primary Care POC Diagnostics Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Technology landscape
• 3.3 Regulatory landscape
• 3.4 Industry impact forces
  • 3.4.1 Growth drivers
    • 3.4.1.1 Upward trend in disease prevalence and demand for quick diagnostics
    • 3.4.1.2 Technological advancements in POCT devices
    • 3.4.1.3 Increasing R&D investment
  • 3.4.2 Industry pitfalls and challenges
    • 3.4.2.1 Stringent regulatory framework
    • 3.4.2.2 High cost of product development
• 3.5 Growth potential analysis
  • 3.5.1 By product
  • 3.5.2 By end-use
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis, 2023
• 4.3 Competitive analysis of major market players, 2023
• 4.4 Competitive positioning matrix, 2023
• 4.5 Strategic outlook matrix, 2023

Chapter 5 Primary Care POC Diagnostics Market Size and Forecast, By Product, 2018-2032 (USD Million)

• 5.1 Key trends, by product
• 5.2 Glucose monitoring
• 5.3 Cardiometabolic testing products
  • 5.3.1 Cardiac marker testing products
    • 5.3.1.1 hsTnl
    • 5.3.1.2 BNP
    • 5.3.1.3 D-dimer
    • 5.3.1.4 CK-MB
    • 5.3.1.5 Myoglobin
    • 5.3.1.6 Other cardiac market testing products
  • 5.3.2 Blood gas/electrolytes testing products
  • 5.3.3 HBA1C testing products
• 5.4 Infectious disease testing products
  • 5.4.1 Influenza testing products
  • 5.4.2 HIV testing products
  • 5.4.3 Hepatitis C testing products
  • 5.4.4 Sexually transmitted disease (STD) testing products
  • 5.4.5 Healthcare-associated infection (HAI) testing products
  • 5.4.6 Respiratory infection testing products
  • 5.4.7 Tropical disease testing products
  • 5.4.8 Other infectious disease testing products
• 5.5 Coagulation testing products
  • 5.5.1 PT/INR testing products
  • 5.5.2 Activated clotting time (ACT/APTT) testing products
• 5.6 Pregnancy and fertility testing products
  • 5.6.1 Pregnancy testing products
  • 5.6.2 Fertility testing products
• 5.7 Tumor/cancer marker testing products
• 5.8 Cholesterol testing products
• 5.9 Hematology testing products
• 5.10 Drug-of-abuse (DoA) testing products
• 5.11 Fecal occult testing products
• 5.12 Urinalysis testing products
• 5.13 Other products

Chapter 6 Primary Care POC Diagnostics Market Size and Forecast, By End-Use, 2018-2032 (USD Million)

• 6.1 Key trends, by end-use
• 6.2 Hospitals
• 6.3 Diagnostic centers
• 6.4 Research laboratories
• 6.5 Home-care settings
• 6.6 Other end-users

Chapter 7 Primary Care POC Diagnostics Market Size and Forecast, By Region, 2018-2032 (USD Million)

• 7.1 Key trends, by region
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 ACON Laboratories, Inc.
• 8.3 Becton, Dickinson, and Company
• 8.4 BioMerieux SA
• 8.5 Bio-Rad Laboratories, Inc.
• 8.6 Dexcom, Inc.
• 8.7 Dragerwerk Ag & Co.
• 8.8 F. Hoffmann-La Roche
• 8.9 HemoCue AB (Danaher Corporation)
• 8.10 Nova Biomedical
• 8.11 Siemens Healthineers AG
• 8.12 Sysmex Corporation